Skip to content

Adults With Moderate to Severe Asthma

A Randomized, Blinded, Multicenter, Parallel Study Comparing the Efficacy and Safety of Pulmicort Respules at 0.5mg QD, 1.0mg QD, 1.0mg Bid, 2.0mg Bid and Pulmicort Turbuhaler at 4.00mcg Bid on Adolescents (12 Yrs of Age and Older) With Adults With Moderate to Severe Asthma.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00642122
Enrollment
900
Registered
2008-03-24
Start date
2003-04-30
Completion date
2004-12-31
Last updated
2011-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma, Pulmicort, budesonide, respules, turbuhaler

Brief summary

A study to compare the safety and effectiveness of 5 different ways of taking Pulmicort when given to asthma patients aged 12 years and above.

Interventions

DRUGBudesonide

0.5mg once daily

Sponsors

AstraZeneca
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female aged 12 or over who have asthma * Ability to properly use an electronic diary * Able and willing to nebulize for up to 20 minutes every morning and evening

Exclusion criteria

* Hospitalised at least one once or required emergency treatment due to asthma in the previous 6 months * Planned hospitalisation during the study * pregnant women or women planning to become pregnant

Design outcomes

Primary

MeasureTime frame
Forced Expiratory Volume in 1 second in patients allocated treatment with Pulmicort REPSULES at 0.5mg and 2.0mg.Day -14, 1, and every 28 days thereafter

Secondary

MeasureTime frame
Percentage of symptom free daysDay -14, 1, and every 28 days thereafter
Percentage of symptom free nightsDay -14, 1, and every 28 days thereafter
Percentage of symptom free 24-hoursDay -14, 1, and every 28 days thereafter

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026